Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma

Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma

Bibliographic Details
Main Authors:	Guido Mioso, Laura Gnesotto, Irene Russo, Stefano Piaserico, Mauro Alaibac
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2023.2182619

Similar Items

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
by: Malin Hultcrantz, et al.
Published: (2024-09-01)

LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE
by: Vincenzo Federico
Published: (2014-08-01)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
by: Anna Marina Liberati, et al.
Published: (2013-01-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Pseudoporphyria Induced by Voriconazole in a 10-year-old Boy: A Case Report and Review of the Literature
by: Francesca Caroppo, et al.
Published: (2023-05-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
by: Tiantao Gao, et al.
Published: (2022-01-01)

Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma
by: Chang-Xin Shi, et al.
Published: (2015-08-01)

Simultaneous myelodisplasia and multiple myeloma successfully treated with lenalidomide
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide
by: Iuliana Vaxman, et al.
Published: (2020-01-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
by: Matthew K. Adams, et al.
Published: (2019-01-01)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
by: Schoenbeck KL, et al.
Published: (2020-05-01)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
by: Schmidt-Wolf, Ingo G. H., et al.
Published: (2011-01-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
by: Yu Isozumi, et al.
Published: (2013-01-01)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
by: Laura Gnesotto, et al.
Published: (2023-03-01)

Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis
by: Stephanie Lakritz, et al.
Published: (2022-09-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01)

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma
by: Kyle T. O’Meara, et al.
Published: (2024-07-01)

Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report
by: Dr. Saqib Raza Khan, et al.
Published: (2022-01-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
by: Alessandra Romano, et al.
Published: (2021-10-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
by: Donna Reece, et al.
Published: (2012-01-01)

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
by: Roberta Martiniani, et al.
Published: (2012-01-01)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
by: Tomoki Ito, et al.
Published: (2018-01-01)

Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?
by: Gloria Orlando, et al.
Published: (2022-05-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone
by: Takuto Tachita, et al.
Published: (2024-07-01)

Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
by: Barbara Lupo, et al.
Published: (2012-01-01)